Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Survodutide showed improvements in metabolic and renal outcomes in a mouse model of diabetic kidney disease, but its relevance to human treatment remains unclear.
Where it sits
this study against the rest of the survodutide (bi 456906) corpusSummary and findings
This study evaluated the effects of survodutide in a mouse model of advanced diabetic kidney disease (DKD). Female obese and diabetic db/db mice received a single intravenous dose of ReninAAV followed by subcutaneous administration of survodutide at 7.5 nmol/kg for 10 weeks. The study assessed various metabolic and renal outcomes.
Abstract
<h4>Aims</h4>Survodutide is a novel long-acting dual glucagon (GCGR)/glucagon-like peptide-1 (GLP-1R) receptor agonist currently in phase-3 clinical development for the treatment of people living with obesity and metabolic dysfunction-associated steatohepatitis. Emerging evidence suggests impaired renal GCGR function in chronic kidney disease (CKD), including diabetic kidney disease (DKD). This study aimed to characterize the effects of survodutide in a translational mouse model of advanced DKD, induced by adeno-associated virus-mediated renin overexpression (ReninAAV) in uninephrectomized (UNx) diabetic db/db mice.<h4>Materials and methods</h4>Female obese and diabetic db/db C57BKS mice received a single intravenous dose of ReninAAV 1 week prior to UNx. Three weeks post-UNx, db/db UNx-ReninAAV mice were administered (s.c., q.d.) vehicle or survodutide (7.5 nmol/kg) for 10 weeks. Endpoints included blood/urine biochemistry, histological markers of glomerulosclerosis, tubular injury and inflammation, as well as quantitative 3D whole-pancreas and whole-kidney imaging.<h4>Results</h4>Compared to vehicle controls, survodutide reduced body weight, hyperglycemia, and HbA1c levels concurrent with improved hyperinsulinemia and β-cell islet volume distribution. Notably, survodutide promoted substantial benefits on advanced albuminuria, severe glomerulosclerosis, kidney hypertrophy and inflammation. 3D whole-kidney imaging revealed that survodutide significantly reduced kidney and glomerular hypertrophy while increasing glomerular density and improving glomerular sphericity. Survodutide reduced liver weight and plasma amino acid levels, including alanine, confirming hepatic glucagon receptor activation.<h4>Conclusions</h4>Survodutide markedly improved metabolic and renal outcomes in the db/db UNx-ReninAAV mouse model of advanced DKD, supporting further investigation into therapeutic options of survodutide in chronic kidney diseases.
Background
This paper addresses the nephroprotective effects of survodutide, a dual GCGR/GLP-1R agonist, in the context of hypertension-accelerated diabetic kidney disease (DKD). Prior research indicates that impaired renal GCGR function is associated with chronic kidney disease, including DKD. Understanding the potential benefits of survodutide could inform future therapeutic strategies for managing kidney disease in diabetic patients.
Methods
The study involved female obese and diabetic db/db C57BKS mice, which received a single intravenous dose of ReninAAV one week prior to uninephrectomy (UNx). Following a 10-week treatment period with survodutide (7.5 nmol/kg, subcutaneously daily), various endpoints were measured, including blood/urine biochemistry and histological markers.
Results
Survodutide treatment resulted in reduced body weight, hyperglycemia, and HbA1c levels. Additionally, it showed improvements in advanced albuminuria, severe glomerulosclerosis, and kidney hypertrophy. Notably, 3D whole-kidney imaging indicated significant reductions in kidney and glomerular hypertrophy, alongside increased glomerular density and improved glomerular sphericity.
Interpretation
The findings suggest that survodutide may have beneficial effects on metabolic and renal outcomes in a mouse model of advanced DKD. However, the clinical significance of these results remains uncertain, as the study is based on animal data, which may not directly translate to human outcomes. Limitations such as the specific genetic background of the mice and the absence of human data should be considered when interpreting these results.
Key findings
- Survodutide reduced body weight, hyperglycemia, and HbA1c levels.
- Survodutide improved advanced albuminuria, severe glomerulosclerosis, kidney hypertrophy, and inflammation.
- 3D whole-kidney imaging revealed a significant reduction in kidney and glomerular hypertrophy.
- Survodutide increased glomerular density and improved glomerular sphericity.
Limitations
- Mouse model may not fully represent human conditions.
- Findings based on a specific genetic background.
- Short treatment duration may not capture long-term effects.
- No human data provided.